The following table details the trading activities
(stock purchases, stock sales, and stock option exercises)
reported to the Securities and Exchange Commission (SEC)
by insider Kakkis Emil D since year 2005.
The trader's CIK number is 1248093.
At the time of this reporting, Kakkis Emil D is the Chief Medical Officer of Biomarin Pharmaceutical Inc .
(stock ticker symbol BMRN).
See this page for all insider trading activities at Biomarin Pharmaceutical Inc .
Stock purchases, sales, and option exercises reported by insider Kakkis Emil D since 2005.
Trade Date
Symbol
Company Name (Issuer)
Trade Type
Shares
Price ($)
Value ($)
2008-06-02
BMRN
Biomarin Pharmaceutical Inc
Option Exercise
16,000
4.00
64,000
2008-06-02
BMRN
Biomarin Pharmaceutical Inc
Sale
18,000
37.63
677,295
2008-04-30
BMRN
Biomarin Pharmaceutical Inc
Purchase
1,640
10.37
17,006
2008-05-01
BMRN
Biomarin Pharmaceutical Inc
Option Exercise
18,000
4.00
72,000
2008-05-01
BMRN
Biomarin Pharmaceutical Inc
Sale
18,000
37.46
674,271
2008-04-29
BMRN
Biomarin Pharmaceutical Inc
Option Exercise
75,000
4.00
300,000
2008-04-01
BMRN
Biomarin Pharmaceutical Inc
Sale
9,857
35.92
354,103
2008-04-01
BMRN
Biomarin Pharmaceutical Inc
Option Exercise
18,000
4.00
72,000
2008-04-01
BMRN
Biomarin Pharmaceutical Inc
Sale
8,143
35.75
291,094
2008-03-06
BMRN
Biomarin Pharmaceutical Inc
Option Exercise
18,000
4.00
72,000
2008-03-06
BMRN
Biomarin Pharmaceutical Inc
Sale
18,000
38.15
686,622
2007-10-31
BMRN
Biomarin Pharmaceutical Inc
Purchase
2,038
6.92
14,100
2007-04-30
BMRN
Biomarin Pharmaceutical Inc
Purchase
2,982
5.18
15,461
2006-01-04
BMRN
Biomarin Pharmaceutical Inc
Option Exercise
50,000
4.00
200,000
2006-10-31
BMRN
Biomarin Pharmaceutical Inc
Purchase
4,368
3.43
14,999
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Kakkis Emil D
(Chief Medical Officer of Biomarin Pharmaceutical Inc at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.
